Asensus Surgical, Inc. (ASXC) Stock

About Asensus Surgical, Inc.

Asensus Surgical, Inc., a medical technology enterprise established in 2006 and headquartered in Durham, North Carolina, focuses on the research, development, and commercialization of robotic medical devices. Its core mission is to elevate minimally invasive surgical procedures throughout the United States, Europe, and Asia through innovative robotic solutions. The company's unique approach involves digitally bridging the gap between surgeons and patients, thereby introducing a new paradigm of "Performance-Guided surgery." This system aims to equip surgeons with critical clinical intelligence, ensuring consistently superior patient outcomes and setting a higher benchmark for surgical standards. Key products include the Senhance Surgical system, a multi-port robotic platform that can maneuver up to four arms to precisely control surgical instruments and a camera during laparoscopic operations. Their product line also features a range of specialized instruments, such as 3mm diameter instruments, 3mm and 5mm hooks, and articulating tools. Additionally, they offer the Senhance ultrasonic system, an advanced energy device designed for accurate, controlled tissue ligation and division. The company, initially known as TransEnterix, Inc., officially rebranded to Asensus Surgical, Inc. in February 2021.

Asensus Surgical, Inc. is headquartered in US.

Asensus Surgical, Inc. (ASXC) stock trades at $0.35 with a market capitalization of $94.92M. The stock is valued at a price-to-earnings (P/E) ratio of -1.12, price-to-book of 2.60, price-to-sales of 11.07. Over the past 52 weeks the stock has ranged between $0.17 and $0.40, and currently trades 12.5% below its 52-week high.

On profitability, Asensus Surgical, Inc. generates a return on equity (ROE) of -117.89%, return on capital employed of -165.88%, an operating margin of -926.52%, a net profit margin of -914.46%.

Official website: www.asensus.com